摘要
目的:研究老年患者P450 2C19基因多态性与以兰索拉唑为基础的三联1周疗法根除幽门螺杆菌疗效的关系。方法:选择125例诊断为幽门螺杆菌阳性的老年患者,同时选择105例年轻的幽门螺杆菌阳性患者为对照组,给予以兰索拉唑为基础的根除幽门螺杆菌治疗,运用AS-PCR方法检测cyp2C19的基因型,根据等位基因功能的缺失,分析CYP2C19基因型与幽门螺杆菌的除菌效果的关系。结果:在这125例老年患者中,检测到纯合子快代谢型,杂合子快代谢型以及慢代谢型,幽门螺杆菌根除率分别为85.29%,76%,89.39%。三者两两比较,差异无显著性(P>0.05)。实验组与对照组的根除率两两比较差异无显著性(P>0.05)。结论 :老年患者CYP2C19基因多态性与以兰索拉唑为基础的三联疗法HP的根除率无相关性。
Objective To investigate the Relationship between the CYP2C19 polymorphism and the efficacy of triple therapy with lansoprazole on Helicobacter pylori infection. Methods 125 elderly patients diagnosed with H.pylori infection were treated with triple therapy. Polymorphism of CYP2C19 was measured by AS-PCR. 105 young patients were selected as control group. The relationship between the polymorphism and eradication rate were analyzed. Results Among the 125 patients,eradication rate of extensive metabolizer group,internal metabolizer group and poor metabolizer groups was 85.29%,76%and 89.39%, respectively. There was no significant difference between groups （P 〉 0.05）. Eradication rate showed no difference between experimental and control group either （P〉0.05）（P〉0.05）. Conclusion The results suggests that the CYP2C19 polymorphism has no correlation with the eradication rate of Helicobacter pylori infection by triple therapy with lansoprazole in elderly patients.
出处
《实用医学杂志》
CAS
北大核心
2014年第20期3242-3244,共3页
The Journal of Practical Medicine
基金
陕西自然科学基金研究项目(编号:2013JC2-14)
西安市卫生局科研立项(编号:2013-7)
